Duke Cancer Institute’s Post

Carmen Calfa, M.D., Clinical Research Lead for the Breast Site Disease Group at the University of Miami Miller School of Medicine, Co-Director of the Cancer Survivorship Program at Sylvester Comprehensive Cancer Center, and Principal Clinical Investigator of the Phase 2 Bria-IMT™ study shares insights on the Bria-IMT™ regimen's unique mechanism of action. The Bria-IMT™ regimen selectively activates adaptive cancer-fighting CD4+ and CD8+ T cells and innate responses (dendritic and NK cells) to activate patients’ immune systems without producing serious side effects. Learn more here: https://bit.ly/3KsI9hV #metastaticbreastcancer #ASCO24

Of the 18.1 million Cancer Survivors in the US, nearly half have lived 10 or more years after their diagnosis, while 19% have lived 20 or more years, as reported in a JNCI Now study led by NCI researchers. These stats are truly encouraging and highlight the progress in cancer research and treatment. It's inspiring to see such significant survival rates among cancer survivors. The next decade will usher precision medicine. Cannot wait for survivorship to rise even further. The future is bright. Source: https://buff.ly/4ilj4Fa

In our latest Ask a Cancer Researcher video, Dr. Saman Maleki talks about the gut microbiome in relation to cancer. Watch to learn why a microbiome transplant might be important for patients undergoing immunotherapy. #immunotherapy #guthealth #microbiome Lawson Health Research Institute Western University

📰 #UpdateYourRefs ⚡New groundbreaking study in #Cell unveiling the #TOPOSCORE based on the ecological topology of gut #microbiota that predicts cancer #immunotherapy outcomes. This innovative approach, which utilizes #metagenomic sequencing data from patients’ feces, identifies specific bacterial communities associated with patient survival. The study’s findings could pave the way for personalized microbiota-centered interventions, enhancing the efficacy of #cancer treatments    ➡ https://lnkd.in/emp3Uxyp Lisa Derosa, Valerio Iebba, Carolina Alves Costa Silva #CancerResearch, #ScienceNews, #MedicalResearch, #Cancer, #HealthcareAdvances, #Immunology, Cell Press

🌟 MVLS Under the Microscope 🌟 Under the lens of a brightfield microscope, HeLa cells—iconic in cancer research—are captured undergoing apoptosis (programmed cell death) following chemotherapy treatment. 💊 This cutting-edge insight helps our researchers at #MVLS understand how cancer therapies work at the cellular level, paving the way for more effective treatments. 🧬 🔬 HeLa cells are derived from one of the most important cell lines in science, originating from cervical cancer cells taken in the 1950s. Their unique ability to replicate indefinitely has made them invaluable for understanding diseases, testing treatments, and advancing medical science. Every discovery brings us one step closer to transforming the future of cancer care 💙 Explore our #FundamentalsOfLife theme - https://lnkd.in/e8-AxCM4 #CancerResearch #CellBiology #HeLaCells #Apoptosis #BrightfieldMicroscopy

Cellular senescence, a dual-edged sword in cancer treatment, poses critical questions: does it potentiate tumor elimination or drive resistance and recurrence? ⚖️🔄 Recent insights by Dr. Yue Liu, Ms. Isabelle Lomeli and Dr. Stephen J. Kron at University of Chicago highlight senescence as both a barrier and a promoter in cancer therapy, influenced by aging, inflammation, and therapeutic interventions like radiation and chemotherapy. 🛡️ 🎯 Strategies to modulate SASP and target SnC persistence are crucial for optimizing cancer treatment outcomes. https://lnkd.in/eFcCSrj2  #CellularSenescence #CancerResearch #Immunotherapy #TherapyResistance

Subsets of colorectal cancer patients display different responses to targeted therapies. In collaboration with Caris Life Sciences, investigators at The University of Texas MD Anderson Cancer Center and their co-authors show how Consensus Molecular Subtyping can help identify patients most likely to experience clinical benefit from immune checkpoint blockade and anti-EGFR therapies. Learn more: https://lnkd.in/gfeS4t87 #CancerResearch #PrecisionMedicine #MolecularProfiling

#HighlyCitedPapers 📝 Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance — Kim, Choi and Lee. In this paper, the authors review #biomarkers that predict the responsiveness of triple-negative breast cancers to #immune checkpoint blockade (ICB) and recent advances in delineating #molecular mechanisms of resistance to ICBs. Full text is available 👇 https://lnkd.in/dziTTRxG #medicine #health #research #science

New research from Technology in Cancer Research & Treatment: Analysis of Expression Pattern and Prognostic Value of the Heparanase in Breast Cancer Through CD274/CTLA-4 Immune Checkpoint Proteins https://lnkd.in/emPvnCpD #cancerresearch #cancertechnology #technology #openaccess #SAGEresearch

Inflammation is fundamentally linked to both aging and cancer, with telomerase playing a crucial role in this connection. Telomeres, the protective caps at the ends of chromosomes, shorten as cells divide, eventually triggering cellular senescence or apoptosis. Chronic inflammation accelerates telomere shortening, promoting aging and increasing the risk of cancer. Understanding the complex relationship between inflammation and telomere dynamics could open new strategies for mitigating aging and preventing cancer. #aging #cancer #inflammation #telomere #telomerase Looking forward.